CTNM — Contineum Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $106.07m
- -$98.69m
Annual cashflow statement for Contineum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -29 | -24.3 | 22.7 | -42.3 |
| Depreciation | ||||
| Non-Cash Items | 2.3 | 5.07 | -2.54 | 3.82 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.108 | -1.27 | -1.02 | 5.33 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -26.3 | -20.1 | 19.3 | -32.8 |
| Capital Expenditures | -0.168 | -0.118 | -0.414 | -0.514 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | -64.8 | 22.4 | -65.2 | -69.2 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -65 | 22.3 | -65.6 | -69.7 |
| Financing Cash Flow Items | 0.096 | -0.004 | -0.371 | 0 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 79.8 | -1.24 | 56.2 | 109 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -11.4 | 0.939 | 9.96 | 6.42 |